UAE Discovers First AI-Designed Drug in Under a Year

The United Arab Emirates just achieved something that usually takes the world's biggest pharmaceutical companies years and billions of dollars to accomplish.

On April 23, 2026, a team of just four scientists in Abu Dhabi announced they've nominated ISM0387, a potential treatment for glioblastoma, one of the deadliest brain cancers. What makes this extraordinary isn't just the science, but the speed: they completed the entire discovery process in under 12 months using artificial intelligence.

Traditional drug discovery is notoriously slow and expensive. Bringing a single medication to market typically costs between $900 million and $2.6 billion and takes over a decade. Even just the early research phase usually consumes 4.5 years.

The UAE team, working for clinical-stage biotech company Insilico Medicine, used AI to dramatically compress that timeline. Their artificial intelligence platform screened 90 novel molecular candidates in just six months, focusing on compounds that could penetrate the brain barrier, a critical requirement for treating glioblastoma.

ISM0387 is what scientists call an MTA-cooperative PRMT5 inhibitor. In simpler terms, it's a new molecule with a unique structure that showed strong results in laboratory disease models. The compound demonstrated improved selectivity and robust effectiveness at multiple doses.

The entire discovery journey happened locally in the UAE. Two computational chemists, one medicinal chemist, and one translational biologist worked together to move from initial design through optimization to this preclinical nomination.

The Ripple Effect

This milestone represents far more than one promising drug candidate. It signals that pharmaceutical innovation is becoming democratized through artificial intelligence.

Countries that previously lacked the massive infrastructure and decades of research experience can now compete in developing life-saving medications. The UAE's achievement demonstrates what Minister of State Saeed bin Mubarak Al Hajeri calls the country's evolution into a "knowledge-based Falcon Economy."

Dr. Fatima Al Kaabi, Director General of the Emirates Drug Establishment, emphasized that this breakthrough reflects "the country's growing ability to develop medicines locally, backed by advanced technologies that are improving how discoveries are made." The implications extend beyond faster research to true pharmaceutical sovereignty and security.

For patients with glioblastoma, who currently face limited treatment options and poor prognoses, ISM0387 represents genuine hope. For the broader scientific community, it proves that AI can deliver on its promise to accelerate medical breakthroughs.

This is also Insilico Medicine's 30th AI-supported preclinical candidate, showing the technology's reproducibility across different therapeutic areas.

The future of drug discovery just got faster, more accessible, and more hopeful.